Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD). Methods: Acute‐phase data from a subset of patients (≥65 years) with GAD were pooled from four randomized, double‐blind, placebo‐controlled trials of duloxetine (3 flexible, 1 fixed dosing). Patients were treated with duloxetine 60–120 mg once daily or placebo for 9–10 weeks. The primary outcome measure was the mean baseline‐to‐endpoint change in Hamilton anxiety scale (HAMA) total score. Secondary measures included the HAMA psychic and somatic anxiety subscales and the Hospital Anxiety Depression Scale (HADS). Results: Of 1491 patients randomly assigned to treatment, 4.9% (duloxetine, n = 45; placebo, n = 28) were ≥ 65 years old. Compared with placebo‐treated patients, duloxetine‐treated patients experienced significantly greater improvements on the HAMA‐total (p = 0.029), the HAMA‐psychic anxiety factor (p = 0.034), HADS‐anxiety (p = 0.049) and ‐depression scales (p = 0.026), but not the HAMA somatic anxiety factor (p = 0.074). Nausea was reported significantly more often in duloxetine‐treated patients (30.0% vs. 7.1%, p = 0.023); duloxetine‐treated patients experienced greater weight loss (p = 0.018). More duloxetine‐treated patients discontinued treatment due to an adverse event (22.2% vs. 0%; p = 0.006). Conclusion: Duloxetine was effective in an elderly patient subset with GAD, although there was a high rate of discontinuations due to adverse events. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anxiety and Depression in Later Life: Co-Occurrence and Communality of Risk Factors
Beekman, A. T. F., de Beurs, E., van Balkom, A. J. L. M., Deeg, D. J. H., van Dyck, R., & van Tilburg, W. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.89 · Cited by 669
Shear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H., Chandler, L., Williams, J., Ali, A., et al. (2001) · Depression and Anxiety · doi:10.1002/da.1033 · Cited by 483
Self-citationRaskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329
Self-citationQuality of life in geriatric generalized anxiety disorder: a preliminary investigation
Loebach Wetherell, J., Thorp, S. R., Patterson, T. L., Golshan, S., Jeste, D. V., & Gatz, M. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.09.003 · Cited by 170
Age at onset of generalized anxiety disorder in older adults
Le Roux, H., Gatz, M., & Wetherell, J. L. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200501000-00005 · Cited by 104
Wise, T. N., Wiltse, C. G., Iosifescu, D. V., Sheridan, M., Xu, J. Y., & Raskin, J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01476.x · Cited by 62 · cited 2×
“Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is efficacious and well tolerated in treating patients with GAD and elderly patients with major depressive disorder (MDD; Raskin et al., 2007; Russell et al., 2007; Wise et al., 2007).”
BackgroundResultSelf-citationThe rater applied performance scale: development and reliability
Lipsitz, J., Kobak, K., Feiger, A., Sikich, D., Moroz, G., & Engelhard, A. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.001 · Cited by 31 · cited 1×
“Inter-rater scoring reliability was assessed using a modified version of the rater applied performance scale (Lipsitz et al., 2004).”
Method
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“tiple RCTs demonstrate that duloxetine [1356] and ven-”
BackgroundA lifespan view of anxiety disorders
Lenze, E. J., & Wetherell, J. L. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/elenze · Cited by 227
Interventions for generalized anxiety disorder in older adults: Systematic review and meta-analysis
Gonçalves, D. C., & Byrne, G. J. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.08.010 · Cited by 227
“Whereas some studies screened participants for cognitive functioning, excluding those below a certain threshold (e.g., Gorenstein et al., 2005; Kimura et al., 2003; Wetherell et al., 2003), others did not report on cognitive functioning (e.g., Davidson et al., 2008; Katz et al., 2002).”
Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?
Hinnell, C., Hurt, C. S., Landau, S., Brown, R. G., Samuel, M., & on behalf of the PROMS‐PD Study Group (2012) · Movement Disorders · doi:10.1002/mds.23961 · Cited by 142
“1 points.(29) Specifically in PD, mean differences of 1.”
BackgroundNew Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments
Andreescu, C., & Varon, D. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0595-8 · Cited by 85
Metadata
- Authors
- Davidson, J., Allgulander, C., Pollack, M. H., Hartford, J., Erickson, J. S., Russell, J. M., Perahia, D., Wohlreich, M. M., Carlson, J., & Raskin, J.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2008-05-14
- Volume
- 23
- Issue
- 6
- Pages
- 519-526
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2098344591
- Cited by
- 57
- References
- 7
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies. https://app.cochat.ai/papers/10.1002/hup.949
- The paper
- Davidson, J., Allgulander, C., Pollack, M. H., Hartford, J., Erickson, J. S., Russell, J. M., Perahia, D., Wohlreich, M. M., Carlson, J., & Raskin, J. (2008). Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.949
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.